RecombinantRabMAb

Recombinant Anti-Rel B antibody [EP613Y] (ab33917)

Submit a review Submit a question References (3)
Western blot - Anti-Rel B antibody [EP613Y] (ab33917)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Rel B antibody [EP613Y] (ab33917)
  • Flow Cytometry (Intracellular) - Anti-Rel B antibody [EP613Y] (ab33917)
  • Immunoprecipitation - Anti-Rel B antibody [EP613Y] (ab33917)
  • Anti-Rel B antibody [EP613Y] (ab33917)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EP613Y] to Rel B
  • Suitable for: Flow Cyt (Intra), WB, IHC-P, IP
  • Reacts with: Human

Conjugates logo Related conjugates and formulations

Alexa Fluor® 488 Alexa Fluor® 647 Carrier Free

Overview

  • Product name

    Anti-Rel B antibody [EP613Y]
    See all Rel B primary antibodies

  • Description

    Rabbit monoclonal [EP613Y] to Rel B

  • Host species

    Rabbit

  • Tested applications

    Suitable for: Flow Cyt (Intra), WB, IHC-P, IPmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide within Human Rel B aa 1-100 (N terminal). The exact sequence is proprietary.

  • Positive control

    • WB: Raji and Daudi cell lysates. IHC-P: Human lymphoma tissue. Flow Cyt (intra): Daudi cells. IP: Raji cells

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab33917 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt (Intra)
1/2000.
WB
1/500. Detects a band of approximately 70 kDa (predicted molecular weight: 62 kDa).
IHC-P
1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
IP
1/50.
Notes
Flow Cyt (Intra)
1/2000.
WB
1/500. Detects a band of approximately 70 kDa (predicted molecular weight: 62 kDa).
IHC-P
1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
IP
1/50.

Target

  • Function

    NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.

  • Sequence similarities

    Contains 1 RHD (Rel-like) domain.

  • Domain

    Both N- and C-terminal domains are required for transcriptional activation.

  • Post-translational
    modifications

    Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.

  • Cellular localization

    Nucleus. Cytoplasm > cytoskeleton > centrosome. Co-localizes with NEK6 in the centrosome.
  • Information by UniProt

  • Database links

    • Alternative names

      • I REL antibody
      • I-Rel antibody
      • IREL antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody
      • relB antibody
      • RELB_HUMAN antibody
      • Reticuloendotheliosis viral oncogene homolog B antibody
      • Transcription factor Rel B antibody
      • Transcription factor RelB antibody
      • v rel avian reticuloendotheliosis viral oncogene homolog B antibody
      • v rel reticuloendotheliosis viral oncogene homolog B antibody
      see all

    Images

    • Western blot - Anti-Rel B antibody [EP613Y] (ab33917)
      Western blot - Anti-Rel B antibody [EP613Y] (ab33917)
      All lanes : Anti-Rel B antibody [EP613Y] (ab33917) at 1/500 dilution

      Lane 1 : Raji cell lysate
      Lane 2 : Daudi cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat anti-rabbit HRP labeled.

      Predicted band size: 62 kDa

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Rel B antibody [EP613Y] (ab33917)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Rel B antibody [EP613Y] (ab33917)

      Immunohistochemical analysis of paraffin-embedded human lymphoma using ab33917

      Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

    • Flow Cytometry (Intracellular) - Anti-Rel B antibody [EP613Y] (ab33917)
      Flow Cytometry (Intracellular) - Anti-Rel B antibody [EP613Y] (ab33917)

      Intracellular Flow Cytometry analysis of Daudi (Human Burkitt's lymphoma lymphoblast) cells labeling Rel B (red) with ab33917 at a 1/2000 dilution. Cells were fixed with 4% paraformaldehyde and permeabilized with 90% methanol. A goat anti-rabbit IgG (Alexa Fluorr® 488) (ab150077) was used as the secondary antibody at a 1/2000 dilution. Black - Rabbit monoclonal IgG (Black) (ab172730). Blue (unlabeled control) - Cell without incubation with primary antibody and secondary antibody (Blue). 

       

       

    • Immunoprecipitation - Anti-Rel B antibody [EP613Y] (ab33917)
      Immunoprecipitation - Anti-Rel B antibody [EP613Y] (ab33917)

      Purified ab33917 at 1/50 dilution (2µg) immunoprecipitating Rel B in Raji whole cell lysate.
      Lane 1 (input): Raji (Human Burkitt's lymphoma B lymphocyte) whole cell lysate 10µg
      Lane 2 (+): ab33917 + Raji whole cell lysate.
      Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab33917 in Raji whole cell lysate.
      VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
      Blocking Buffer and concentration: 5% NFDM/TBST.
      Diluting buffer and concentration: 5% NFDM/TBST.
      Observed band size: 62 kDa

    • Anti-Rel B antibody [EP613Y] (ab33917)
      Anti-Rel B antibody [EP613Y] (ab33917)

    Protocols

    To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

    Click here to view the general protocols

    References (3)

    Publishing research using ab33917? Please let us know so that we can cite the reference in this datasheet.

    ab33917 has been referenced in 3 publications.

    • Siak JJ  et al. The nuclear-factor kappaB pathway is activated in pterygium. Invest Ophthalmol Vis Sci 52:230-6 (2011). PubMed: 20811049
    • McMillan DH  et al. Lung-targeted overexpression of the NF-?B member RelB inhibits cigarette smoke-induced inflammation. Am J Pathol 179:125-33 (2011). PubMed: 21703398
    • Huang Y  et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115:1226-37 (2010). PubMed: 19965620

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab33917.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com